Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.

The pharmacogenomics journal - 1 Feb 2022

Quintanilha Julia C F, Racioppi Alessandro, Wang Jin, Etheridge Amy S, Denning Stefanie, Peña Carol E, Skol Andrew D, Crona Daniel J, Lin Danyu, Innocenti Federico

Abstract excerpt

No biomarkers are available to predict patients at risk of developing hypertension induced by VEGF-pathway inhibitors. This study aimed to identify predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach. The discovery set included 140 sorafenib-treated patients (TARGET study) genotyped for 973 SNPs in 56 genes. The most statistically significant SNPs associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypertension

Share to Linkage Disequilibrium

Share to Phosphatidylinositol 3-Kinase

Share to Predictive Value of Tests

Share to Risk Assessment

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 34775477
DOI: 10.1038/s41397-021-00261-5
PMCID: PMC8799524

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors.PMID 34775477Read ↗

Genetic markers of bevacizumab-induced hypertension.Semantic proximity Read ↗

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Semantic proximity Read ↗

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.Semantic proximity Read ↗

Genetic predisposition to bevacizumab-induced hypertension.Semantic proximity Read ↗

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.Semantic proximity Read ↗

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).Semantic proximity Read ↗

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinibSemantic proximity Read ↗

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.Semantic proximity Read ↗

Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.Semantic proximity Read ↗

Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.Semantic proximity Read ↗

Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.